Table 2.
Baseline patient characteristics for hospitalized patients with COVID-19, pre and post introduction of molecular point-of-care testing (mPOCT).
| Pre mPOCTgroupn = 654 | Post mPOCTgroupn = 1782 | Difference(95%CI) | p valuea | |
|---|---|---|---|---|
| Age, years | 72.6 [55.9–83.4] | 64.8 [49.7–79.4] | 7.8 (7.3–8.4) | < 0.0001 |
| Male Sex | 280 (42.8%) | 832 (46.7%) | 3.9% (2.4–5.4) | 0.0977 |
| BMIb | 26.9 [23.8–31.1] | 27.9 [23.9–32.9] | 1 (0.8–1.2) | 0.0039 |
| BAMEc | 59 (10.2%) | 156 (10.1%) | 0.1% (0.1–0.1) | 1.0000 |
| Asthma | 115 (17.6%) | 298 (16.7%) | 0.9% (0.3–2.1) | 0.6591 |
| COPD | 123 (18.8%) | 261 (14.6%) | 4.2% (2.8–5.5) | 0.0149 |
| CKD | 123 (18.8%) | 228 (12.8%) | 6.0% (4.6–7.5) | 0.0002 |
| Diabetes | 179 (27.4%) | 407 (22.8%) | 4.5% (3.1–6) | 0.0235 |
| Dementia | 75 (11.5%) | 145 (8.1%) | 3.3% (2.15–4.5) | 0.0138 |
| Hypertension | 256 (39.1%) | 526 (29.5%) | 9.6% (8–11.3) | < 0.0001 |
| IHD | 166 (25.4%) | 400 (22.4%) | 2.9% (1.5–4.3) | 0.1426 |
| CCF | 154 (23.5%) | 322 (18.1%) | 5.5% (4.0–7.0) | 0.0030 |
| Cirrhosis | 41 (6.3%) | 126 (7.1%) | 0.8% (0.1–1.5) | 0.5463 |
| CCI | 5.2 (1.8–8.7) | 4.2 (0.75–7.6) | 1 (0.9–1.1) | < 0.0001 |
All data are presented as n (%), median [interquartile range] or mean (SD). CI, confidence interval. BMI, body mass index. BAME, black and minority ethic. COPD, chronic obstructive airways disease. CKD, chronic kidney disease. IHD, ischaemic heart disease. CCF, congestive cardiac failure. CCI, Charlson comorbidity index.
a
Mann Whitney U Test, Chi squared or Fisher's Exact Test.
b
Assessed in 494 and 1255 patients in the pre and post implementation groups, respectively.
c
Assessed in 581 and 1551 patients in the pre and post implementation groups, respectively.